(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain

Pharmacology and Toxicology

Volumn 82, Issue 2, 1998, Pages 57-66

  Knoll, Joseph ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATALASE; LEVODOPA; SELEGILINE; SUPEROXIDE DISMUTASE;

AGING; ALZHEIMER DISEASE; BRAIN; CATECHOLAMINERGIC SYSTEM; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PERFORMANCE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0031907334     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1998.tb01399.x     Document Type: Review

References (90)

1. Albin, R. L., A. B. Young & J. B. Penney: The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12, 366-375.
2. Allain H., J. Gougnard & H. C. Naukirek: Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMP), Acta neurol scand. 1991, 136, 73-78.
3. Barger, G. & H. H. Dale: Chemical structure and sympathomimetic action of amines. J. Physiol. (London) 1910, 41, 19-59.
4. Birkmayer, W. & O. Hornykiewicz: Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinesie. Wien. Klin. Wochenschrift, 1961, 73, 787-788.
5. Birkmayer, W. & O. Hornykiewicz: Der L-Dioxyphenyl-alanin-Effekt beim Parkinson Syndrom des Menschen. Arch. Psychiat. Nervenkrh. 1962, 203, 560-564.
6. Birkmayer, W. & P. Riederer: Die Parkinson-Krankheit. Springer-Verlag, Wien, New York, 1980, p. 217.
7. Birkmayer, W., P. Riederer, L. Ambrozi & M. B. H. Youdim: Implications of combined treatment with "Madopar" and L-Deprenil in Parkinson's disease. Lancet 1977, 1, 439-443.
8. Birkmayer, W., J. Knoll, P. Riederer, M. B. H. Youdim, V. Hars & J. Marton: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J. Neural Transm. 1985, 64, 113-127.
9. Blackwell, B.: Hypertensive crisis due to monoamine oxidase inhibitors. Lancet 1963, II, 849-851.
10. Burke, W. J., W. H. Roccaforte, S. P. Wengel, B. L. Bayer, A. E. Ranno & N. K. Willcockson: L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J. Amer. Geriatr. Soc. 1993, 41, 1219-1225.
11. Burn, J. H. & M. J. Rand: The action of sympathomimetic amines in animals treated with reserpine. J. Physiol. (Lond.) 1958, 144, 314-336.
12. Carrillo, M. C., S. Kanai, M. Nokubo & K. Kitani: (-)Deprenyl induces activities of both superoxide dismutase and catalase hut not of glutathion peroxidase in the striatum of young male rats. Life Sci. 1991, 48, 517-521.
13. Carrillo, M. C., S. Kanai, M. Nokubo, G. O. Ivy, Y. Sato & K. Kitani: (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp. Neurol. 1992, 116, 286-294.
14. Cohen, G., P. Pasik, B. Cohen, A. Leist, C. Mitileneou & M. D. Yahr: Pargyline and (-)deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 1984, 106, 209-210.
15. Colombo, C. & P. Spica: Sopra alcuni derivati alfatoluici. Gazz. Chim. Ital. 1875, 5, 124-125.
16. Dobbs, S. M. R. J. Dobbs & A. Charlett: Multi-centre trials: U-turns by bandwagons and the patient left by the wayside. Brit. J. Clin. Pharmacol. 1996, 42, 143-145.
17. Ehringer, H. & O. Hornykiewicz: Verteilung von Noradrenaline und Dopamine im Gehirn des Menschen und ihre Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien. Klin. Wochenschrift 1960, 38, 1236-1239.
18. Elsworth, J. D., V. Glover, G. P. Reynolds, M. Sandler, A. J. Lees, P. Phuapradit, K. M. Shaw, G.M. Stern & P. Kumar: Deprenyl administration in man; a selective monoamine oxidase B inhibitor without the "cheese effect". Psychopharmacology 1978, 57, 33-38.
19. Finnegan, K. T. J. J. Skratt, I. Irvin, L. E. DeLanney & Langston J. W: Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur. J. Pharmacol. 1990, 184, 119-126.
20. Fischer, E., B. Heller & A. H. Miró: β-Phenylethylamine in human urine. Arzneimittelf. 1968, 18, 1486.
21. Graham, D. G.: On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med. 1979, 103, 359-362.
22. Hall, D. W. R., B. W. Logan & G. H. Parsons: Further studies on the inhibition of monoamine oxidase by MB 9302 (clorgyline). Biochem. Pharmacol. 1969, 18, 1447-1454.
23. Hársing, R. G., K. Magyar, K. Tekes, E. S. Vizi & J. Knoll: Inhibition by (-)-deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. Pol. J. Pharmacol. Pharm. 1979, 31, 297-307.
24. Johnston, J. P.: Some observations upon a new inhibitor of monoamine oxidase in human brain. Biochem. Pharmacol. 1968, 17, 1285-1297.
25. Joseph, J. A., R. E. Berger & B. T. Engel: Age related changes in the nigrostriatum. A behavioral and biochemical analysis. J. Gerontol. 1978, 33, 643-650.
26. Kitani, K., S. Kanai, Y. Sato, M. Ohta, G. O. Ivy & M. C. Carillo: Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci. 1992, 52, 281-288.
27. Knoll, J.: Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine oxidase and its inhibition. Eds.: G. E. S. Wolstenholme, J. Knight, Ciba foundation Symposium 39 (new series). Elsevier, Amsterdam, 1976, 131-161.
28. Knoll, J.: The possible mechanism of action of (-)deprenyl in Parkinson's disease. J. Neural Transm. 1978, 43, 177-198.
29. Knoll, J.: (-)Deprenyl the MAO inhibitor without the 'cheese effect'. Trends Neurosci. 1979, 1, 111-113.
30. Knoll, J.: Selective inhibition of B type monoamine oxidase in the brain: a drug strategy to improve the quality of life in senescence. In: Strategy in drug research. Ed.: J. A. Keverling Buisman, Elsevier, Amsterdam, 1982, 107-135.
31. Knoll, J.: Deprenyl (selegiline). The history of its development and pharmacological action. Acta Neurol. Scand. 1983, Suppl. 95, 57-80.
32. Knoll, J.: Striatal dopamine, aging and deprenyl. In: Dopamine, ageing and diseases. Eds. J.: Borsy, L. Kerecsen & L. György, Pergamon Press, Akadémiai Kiadó, Budapest, 1986, 7-26.
33. R) facilitates the activity of the nigrostriatal dopaminergic neuron. J. Neural Transm. 1987, 25, 45-66.
34. Knoll, J.: The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl. Mech. Ageing & Dev. 1988, 46, 237-262.
35. Knoll, J.: The pharmacology of selegiline /(-)deprenyl/. Acta Neurol. Scand. 1989, 126, 83-91.
36. Knoll, J.: Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. Adv. Neurol. 1990, 53, 425-429.
37. Knoll, J.: Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. Medicinal Res. Rev. 1992, 12, 505-524.
38. Knoll, J.: The pharmacological basis of the beneficial effect of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural. Transm. 1993, Suppl. 40, 69-91.
39. Knoll, J.: Memories of my 45 years in research. Pharmacology & Toxicology 1994, 75, 65-72.
40. Knoll, J.: Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. Biomed. & Pharmacother. 1995, 49, 187-195.
41. Knoll, J.: (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment. Biomed. & Pharmacother. 1996, 50, 315-317.
42. Knoll, J. & K. Magyar: Some puzzling effects of monoamine oxidase inhibitors. Adv. Bioch. Psychopharmacol. 1972, 5, 393-408.
43. Knoll, J. & I. Miklya: Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-Binhibition. Arch. int. Pharmacodyn. Thér. 1994, 328, 1-15.
44. Knoll, J. & I. Miklya: Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity. Rationale for prophylactic (-)deprenyl (selegiline) medication. Life Sci. 1995, 56, 611-620.
45. Knoll, J., Z. Ecseri, K. Kelemen, J. Nievel & B. Knoll: Phenylisopropylmethyl propinylamine (E-250) a new psychic energizer. Arch. int. Pharmacodyn. Thér. 1965, 155, 154-164.
46. Knoll, J., E. Sz. Vizi & Gy. Somogyi: Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimittelf. 1968, 18, 109-112.
47. Knoll, J., T. T. Yen & J. Dalló: Long-lasting, true aphrodisiac effect of (-)deprenyl in sexually sluggish old male rats. Mod. Probl. Pharmacopsychiat. 1983, 19c 135-153.
48. Knoll, J., J. Dallo & T. T. Yen: Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci. 1989, 45, 525-531.
49. Knoll, J., B. Knoll, Z. Török, J. Timár & S. Yasar: The pharmacology of 1-phenyl-2-propylaminopentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Arch. int. Pharmacodyn. Thér. 1992a, 316, 5-29.
50. Knoll, J., V. Tóth, M. Kummert & J. Sugár: (-)Deprenyl and (-)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. Mech. Ageing & Der. 1992b, 63, 157-163.
51. Knoll, J., T. T. Yen & I. Miklya: Sexually low performing male rats dies earlier than their high performing peers and (-)deprenyl treatment eliminates this difference. Life Sci. 1994, 54, 1047 1057.
52. Knoll, J., I. Miklya, B. Knoll., R. Markó & K. Kelemen: (-)-Deprenyl and (-)1-phenyl-2-propylaminopentane. [(-)PPAP], act primarily as potent stimulants of action potential - transmitter release coupling in the catecholaminergic neurons. Life Sci. 1996a, 58, 817-827.
53. Knoll, J., I. Miklya, B. Knoll, R. Markó, & D. Rácz: Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sci. 1996b, 58, 2101-2114.
54. Knollema, S., W. Aukema, H. Hom, J. Horf, J. Gert & T. Horst: L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 1995, 26, 1883-1887.
55. Lees, A. J.: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J. 1995, 311, 1602-1607.
56. Mangoni, A., M. P. Grassi, L. Frattola, R. Piolti, S. Bassi & A. Motta: Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur. Neurol. 1991, 31, 100-107.
57. Mann, J. J. & S. Gershon: A selective monoamine oxidase-B inhibitor in endogenous depression. Life Sci. 1980, 26, 877-882.
58. Martin, C.: Sexual activity in the aging male. In: Handbook of sexology. Eds. J. Money, H. Musaph, Elsevier, Amsterdam, 1977, 813-824.
59. Martini, E., I. Pataky, K. Szilágyi & V. Venter: Brief information on an early phase-II study with (-)deprenyl in demented patients. Pharmacopsychiatry 1987, 20, 256-257.
60. Milgram, M. W., R. J. Racine, P. Nellis, A. Mendoca & G. O. Ivy: Maintenance on L-(-)deprenyl prolongs life in aged male rats. Life Sci. 1990, 47, 415-420.
61. Mink, J. W. & W. T. Thach: Basal ganglia intrinsic circuits and their role in behavior. Curr. Opinion in Neurobiol. 1993, 3, 950-957.
62. Myttyla V. V., K. A. Sotaniemi, J. A. Vourinen & E. H. Heinonen: Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992, 42, 339-343.
63. Nakajima, T., Y. Kakimoto & I. Sano: Formation of β-phenylethylamine in mammalian tissue and its effect on motor activity. J. Pharm. 1964, 143, 319-325.
64. Olanow C. W., J. H., W. Koller: Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Patients taking selegiline may have received more levodopa than necessary. Br. Med. J. 1996, 312, 702-703.
65. Parkinson Study Group: Effect of (-)deprenyl on the progression disability in early Parkinson's disease. New Engl. J. Med. 1989, 321, 1364-1371.
66. Parkinson Study Group: Effect to tocopherol and (-)deprenyl on the progression of disability in early Parkinson's disease. New Engl. J. Med. 1993, 328, 176-183.
67. Parkinson Study Group: Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol. 1996, 39, 37-45.
68. Piccinin, G. L., G. C. Finali & M. Piccirilli: Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin. Neuropharmacol. 1990, 13, 147-163.
69. Prinzmetal, M. & W. Bloomberg: The use of benzedrine for the treatment of narcolepsy. JAMA. 1935, 105, 2051-2054.
70. Rinne, J. O., M. Röyttä, L. Paljärvi, J. Rummukainen & U. K. Rinne: Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 1991, 41, 859-861.
71. Rogers, J. & F. E. Bloom: Neurotransmitter metabolism and function in aging central nervous system. In. Handbook an the biology of aging. Eds. C. E. Finch & E. L. Schneider, Van Nostrand Reinhold, New York, 1985, 645-657.
72. Ruehl, W. W., T. L. Entriken, B. A. Muggenberg, D. S. Bruyette, W. G. Griffith & F. F. Hahn: Treatment with L-deprenyl prolongs life in elderly dogs. Life Sci. 1997, 61, 1037-1044.
73. Sano, M., C. Ernesto, R. G. Thomas, M. R. Klauber, K. Schafer, M. Grundman, P. Woodbury, J. Growdon, C. W. Cotman, E. Pfeiffer, L. S. Schneider, & L. J. Thal: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New Engl. J. Med. 1997, 336, 1216-1222.
74. Salonen, T., A. Haapalinna, E. Heinonen, J. Suhonen & A. Hervonen: Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol. 1996, 91, 466-474.
75. Severson, J. A. & C. E. Finch: Reduced dopaminergic binding during aging in the rodent striatum. Brain Res. 1980, 192, 147-162.
76. Standaert D. G. & A. B. Young: Treatment of central nervous system degenerative disorders. In: Goodman & Gilman's The pharmacological basis of therapeutics. Ninth Edition. Eds. J.G. Hardman & L. E. Limbird, McGraw-Hill, New York, 1996, 503-519.
77. Tariot, P. N., R. M. Cohen, T. Sunderland, P. A. Newhouse, D. Yount & A. M. Mellow: L-(-)Deprenyl in Alzheimer's disease. Arch. Gen. Psychiatry. 1987, 44, 427-433.
78. Tatton, W. G. & C. E. Greenwood: Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 1991, 30, 666-672.
79. Tatton, W. G., W. Y. L. Yu, D. P. Holland, C. Tai & Kwan M.: (-)-Deprenyl reduces apoptosis by inducing new protein synthesis. J. Neurochem. 1994, 63, 1572-1575.
80. Tetrud, J. W. & J. W. Langston: The effect of (-)deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245, 519-522.
81. 1H-ADTN binding sites in rabbit brain with aging. Brain Res. 1980, 192, 185-194.
82. Tringer, L., G. Haits & E. Varga: The effect of L-E-250 (-L-phenyl-isopropylmethyl-propinyl-amine HCl) in depression. In: V. Conferentia Hungarica pro Therapia el Investigatione in Pharmacologia. Ed.: G. Leszkovszky, Akadémiai Kiadó, Budapest, 1971, 111-114.
83. Tóth, V., M. Kummert, J. Sugár & J. Knoll: A procedure for measuring neuromelanin in neurocytes by a TV-image analyser. Mech. Ageing & Dev. 1992, 63, 215-221.
84. Varga, E.: Vorläufiger Bericht über die Wirkung des Präparats E-250 (phenyl-isopropyl-methyl-propinylamine-chlorhydrat) In: III. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. Ed.: B. Dumbovich, Akadémiai Kiadó, Budapest. 1965, 197-201.
85. Varga, E. & L. Tringer: Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine HCl, E-250). Acta Med. Acad. Sci. Hung. 1967, 23, 289-295.
86. Vizuete, M. L., V. Steffen, A. Ayala, J. Cano & A. Machado: Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum. Neurosci. Lett. 1993, 152, 113-116.
87. + in vivo. Eur. J. Pharmacol. 1993, 243, 241-247.
88. Yasar, S., G. Winger, B. Nickel, G. Schulze & S. R. Goldberg: Preclinical evaluation of 1-deprenyl: lack of amphetamine-like abuse potential. In: Inhibitors of Monoamine Oxidase B. Ed. I. Szelenyi, Birkhäuser Verlag, Basel, 1993, 215-233.
89. Yu, W. Y., D. P. Holland & W. G. Tatton: Deprenyl alters the time course of death of axotomized facial motoneurons and the hypertrophy of neighboring astrocytes in immature rats. Exp. Neurol. 1994, 126, 233-246.
90. Zhang, F., P. M. Richardson, D. P. Holland, Q. Guo & W.G. Tatton: CNTF or (-)-deprenyl in immature rats: survival of axotomized facial motoneurons and weight loss. J. Neurosci. Res. 1995, 40, 464-570.